{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibihklynl6wkkxu4izhbmeni2fodhkivcw6teaxcrjt7vqi6telcu",
    "uri": "at://did:plc:nnaxwirbqywidimahadp42bj/app.bsky.feed.post/3mojey5bafq42"
  },
  "path": "/alkermes-presents-detailed-positive-results-from-vibrance-2-phase-2-study-of-alixorexton-in-adults-with-narcolepsy-type-2-at-sleep-2026/",
  "publishedAt": "2026-06-17T21:02:28.000Z",
  "site": "https://www.cityam.com",
  "tags": [
    "Conference",
    "Product/Service"
  ],
  "textContent": "— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to Placebo in Narcolepsy Type 2 — — Improvements in Wakefulness and Patient-Reported Cognition and Fatigue Were Sustained Through 13 Weeks — — Alixorexton Was Generally Well Tolerated at All Doses Tested —",
  "title": "Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026"
}